Brief: LumiraDx Has Commenced Shipments In Europe For Its Covid-19 & Flu A/B Microfluidic Antigen Test
11/01/2022 14:45
Jan 11 (Reuters) - LumiraDx Ltd LMDX.O :
* LUMIRADX HAS COMMENCED SHIPMENTS IN EUROPE FOR ITS
COVID-19 &
FLU A/B MICROFLUIDIC ANTIGEN TEST
* LUMIRADX - SEES 2021 FULL-YEAR REVENUES OF $422 MILLION
* LUMIRADX - SEES 2021 Q4 REVENUES OF $119 MILLION
* LUMIRADX LTD - LUMIRADX POINT OF CARE COVID-19
MICROFLUIDIC
ANTIGEN TEST IS EXPECTED TO ACCOUNT FOR $77 MILLION OF REVENUE
IN Q4 OF 2021
Source text for Eikon: ID:nPn1xLFYJa
Further company coverage: LMDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on LumiraDx
See all newsBrief: LumiraDx Announces Its Securities Will Be Suspended From Trading On Nasdaq At The Open Of Business On January 9Th
Roche to buy part of LumiraDx diagnostics platform for $295 million
Brief: LumiraDx- Under Terms Of Certain Loan Agreement, Dated March 23, 2021, The Waiver Period Has Expired As Of Today
Brief: LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
Brief: Willard L. Umphrey Reports 10.31% Stake In Lumiradx Limited As Of Dec 22- SEC Filing